文献速递物质与行为成瘾

司美格鲁肽与真实世界人群中大麻使用障碍发生率及复发率降低的关联:一项回顾性队列研究

Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.
PubMed 文献 · Mol Psychiatry · 2024-03-14

该回顾性队列研究基于TriNetX电子健康记录网络,比较司美格鲁肽与非GLP-1RA抗肥胖或抗糖尿病药物在大麻使用障碍(CUD)发生和复发上的关联。在肥胖患者中,司美格鲁肽与CUD发生风险降低(HR 0.56,95%CI 0.42-0.75)及复发风险降低(HR 0.62,95%CI 0.46-0.84)相关;2型糖尿病(T2D)人群结果类似。

要点

  • 肥胖患者中司美格鲁肽与CUD发生风险降低相关(HR 0.56,95%CI 0.42-0.75)。
  • 有CUD史者中司美格鲁肽与复发风险降低相关(HR 0.62,95%CI 0.46-0.84)。
  • T2D人群结果类似,但复发关联的95%CI跨越1(HR 0.66,95%CI 0.42-1.03)。

核心结论

  • 在真实世界肥胖和T2D人群中,司美格鲁肽与非GLP-1RA抗肥胖或抗糖尿病药物相比,与CUD发生和复发诊断风险降低相关。
  • 作者指出这些仅为初步证据,需进一步临床前研究阐明机制,并需随机临床试验支持其临床用于CUD。

研究设计与样本

  • 通过倾向评分匹配比较司美格鲁肽与非GLP-1RA抗肥胖或抗糖尿病药物队列,计算12个月随访期间CUD发生和复发的风险比(HR)及95%置信区间(CI)。
  • 研究人群包括85,223例肥胖患者,并在596,045例T2D患者中复制分析。

主要发现

  • 肥胖患者(平均年龄51.3岁,65.6%女性)中,无CUD史者司美格鲁肽与CUD发生风险降低相关(HR 0.56,95%CI 0.42-0.75)。
  • 肥胖患者中有CUD史者司美格鲁肽与CUD复发诊断风险降低相关(HR 0.62,95%CI 0.46-0.84)。
  • 按性别、年龄组、种族及有无T2D分层,均观察到一致的降低趋势。
  • T2D人群中,司美格鲁肽与非GLP-1RA抗糖尿病药物相比,CUD发生HR 0.40(95%CI 0.29-0.56),复发HR 0.66(95%CI 0.42-1.03)。

临床怎么用

  • 对于合并肥胖或T2D且存在CUD风险或病史的患者,司美格鲁肽的使用可能与CUD发生和复发风险降低相关,可作为临床评估时的参考信息。
  • 目前证据仅为观察性关联,不能据此将司美格鲁肽用于CUD的临床治疗,需等待随机临床试验验证。

局限性

  • 研究为回顾性队列设计,可能存在未测量的混杂因素。
  • 作者指出需要进一步临床前研究理解机制,并需随机临床试验支持临床使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cannabis is the most frequently used illicit drug in the United States with more than 45 million users of whom one-third suffer from a cannabis use disorder (CUD). Despite its high prevalence, there are currently no FDA-approved medications for CUD. Patients treated with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for treating type 2 diabetes (T2D) and for weight management have reported reduced desire to drink and smoke. Preclinical studies have shown that semaglutide decreased nicotine and alcohol consumption. Preclinical and preliminary clinical evidence of semaglutide's potential beneficial effects on various substance use disorders led us to evaluate if it pertained to CUD. In this retrospective cohort study of electronic health records (EHRs) from the TriNetX Analytics Network, a global federated health research network of approximately 105.3 million patients from 61 large healthcare organizations in the US, we aimed to assess the associations of semaglutide with both incident and recurrent CUD diagnosis compared to non-GLP-1RA anti-obesity or anti-diabetes medications. Hazard ratio (HR) and 95% confidence intervals (CI) of incident and recurrent CUD were calculated for 12-month follow-up by comparing propensity-score matched patient cohorts. The study population included 85,223 patients with obesity who were prescribed semaglutide or non-GLP-1RA anti-obesity medications, with the findings replicated in 596,045 patients with T2D. In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.42-0.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.46-0.84). Consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without T2D. Similar findings were replicated in the study population with T2D when comparing semaglutide with non-GLP-1RA anti-diabetes medications for incident CUD (HR: 0.40, 95% CI: 0.29-0.56) and recurrent CUD (HR: 0.66, 95% CI: 0.42-1.03). While these findings provide preliminary evidence of the potential benefit of semaglutide in CUD in real-world populations, further preclinical studies are warranted to understand the underlying mechanism and randomized clinical trials are needed to support its use clinically for CUD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol Psychiatry. 2024. PMID: 38486046. doi:10.1038/s41380-024-02498-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。